©The Author(s) 2026.
World J Gastroenterol. Feb 28, 2026; 32(8): 113299
Published online Feb 28, 2026. doi: 10.3748/wjg.v32.i8.113299
Published online Feb 28, 2026. doi: 10.3748/wjg.v32.i8.113299
Figure 7 Combination of V8 and bortezomib suppresses patient-derived organoid growth.
A: Scheme of patient-derived organoid culture and representative images (scale bar: 500 μm); B and C: Sensitivity of organoids to V8 and bortezomib (BTZ) was examined for 24 hours and 48 hours; D-F: Viability of organoids was evaluated in response to combination of V8 and BTZ treatment for 24 hours and 48 hours. Representative images (D) and heatmap of cell viability (E: 24 hours; F: 48 hours) are shown (scale bar: 500 μm). BTZ: Bortezomib.
- Citation: Li SC, Shao SZ, Zhang YH, Zhou Y, Shang WT, Gao Y, He QB, Guo QL, Guo CY, Zhang XB. Wogonin derivative V8 enhances bortezomib efficacy in gastric carcinoma by disrupting lysosome-mediated drug resistance. World J Gastroenterol 2026; 32(8): 113299
- URL: https://www.wjgnet.com/1007-9327/full/v32/i8/113299.htm
- DOI: https://dx.doi.org/10.3748/wjg.v32.i8.113299